TABLE 2.
Characteristics | HR | 95% CI | P‐value |
---|---|---|---|
Overall survival | |||
Multivariate analysis of YAP expression (Figure 1E) | |||
Age | 1.025 | 1.011‐1.040 | .000 |
Pathologic stage | |||
II vs I | 2.156 | 0.778‐5.979 | .140 |
III vs I | 3.917 | 1.440‐10.656 | .007 |
YAP expression (high vs low) | 1.940 | 1.050‐3.583 | .034 |
Multivariate analysis of AXL expression (Figure 1F) | |||
Age | 1.025 | 1.011‐1.039 | .000 |
Pathologic stage | |||
II vs I | 2.147 | 0.774‐5.952 | .142 |
III vs I | 3.621 | 1.331‐9.852 | .012 |
AXL expression (high vs low) | 1.571 | 1.100‐2.244 | .013 |
Multivariate analysis of combined YAP and AXL expression (Figure 1G) | |||
Age | 1.025 | 1.012‐1.040 | .000 |
Pathologic stage | |||
II vs I | 2.165 | 0.781‐6.002 | .138 |
III vs I | 3.792 | 1.393‐10.320 | .009 |
YAP/AXL expression | |||
YAPHi/AXLLo & YAPLo/AXLHi vs YAPLo/ AXLLo | 1.923 | 1.006‐3.676 | .048 |
YAPHi/ AXLHi vs YAPHi/AXLLo & YAPLo/AXLHi | 2.013 | 1.281‐3.163 | .002 |
P‐values in bold print indicate statistical significance.
Abbreviations: CI, confidence interval; HR, hazard ratio.